Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Autor: Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Rok vydání: 2023
DOI: 10.1158/1078-0432.22464945
Popis: Supplemental Figure 2. Arithmetic mean concentration-time curves for fasted patients receiving 225 mg of ensartinib on Days 1 and 22 of Cycle 1.
Databáze: OpenAIRE